CRIS Quote, Trading Chart, Curis Inc.
home / stock / cris / cris quote
$9.98 Last:
-1.48% Change Percent:
$9.93 Open:
$9.98 Previous Close:
$10.15 High:
$9.55 Low:
385,459 Volume:
03/03/2021 12:35:10 pm Last Trade Date Time:
Quotes are delayed by 15 to 20 minutes.
Last Five Trading Days
| Stock Date | Open Price | Close Price | High | Low | Volume |
|---|---|---|---|---|---|
| 2021-03-03 | 9.93 | 9.98 | 10.15 | 9.55 | 385,459 |
| 2021-03-02 | 10.19 | 10.13 | 10.35 | 10.01 | 1,287,139 |
| 2021-03-01 | 10.2354 | 10.43 | 10.53 | 10.01 | 1,716,848 |
| 2021-02-26 | 9.8 | 9.84 | 10.09 | 9.39 | 1,332,235 |
| 2021-02-25 | 9.83 | 9.75 | 10.14 | 9.46 | 1,120,970 |
| 2021-02-24 | 9.85 | 9.93 | 10.17 | 9.62 | 806,169 |
| 2021-02-23 | 9.75 | 9.69 | 9.98 | 9.01 | 1,699,947 |
| 2021-02-22 | 10.1348 | 10.08 | 10.25 | 9.86 | 1,843,835 |
| 2021-02-19 | 10.67 | 10.27 | 10.67 | 10.16 | 897,475 |
| 2021-02-18 | 10.67 | 10.51 | 10.98 | 10.27 | 1,441,199 |
| 2021-02-17 | 10.35 | 11.07 | 11.09 | 10.25 | 2,144,855 |
| 2021-02-16 | 10.8 | 10.57 | 10.82 | 10.2 | 1,542,245 |
| 2021-02-15 | 10.54 | 10.8 | 10.9 | 10.12 | 2,148,908 |
| 2021-02-12 | 10.54 | 10.8 | 10.9 | 10.12 | 2,127,733 |
| 2021-02-11 | 10.9436 | 10.87 | 12.29 | 10.7 | 6,726,694 |
| 2021-02-10 | 10.02 | 9.76 | 10.1 | 9.34 | 1,535,262 |
| 2021-02-09 | 9.95 | 9.765 | 10.04 | 9.57 | 1,697,480 |
| 2021-02-08 | 10.31 | 9.96 | 10.55 | 9.79 | 1,934,068 |
| 2021-02-05 | 10.34 | 10.24 | 10.3499 | 9.915 | 1,054,709 |
| 2021-02-04 | 10.6188 | 10.38 | 10.65 | 10.16 | 883,153 |
News, Short Squeeze, Breakout and More Instantly...
-
Curis Doses First Patient in Phase 1 Study of CA-4948 in Combination with Ibrutinib in Patients with Relapsed or Refractory Hematologic Malignancies - Amends existing protocol of ongoing Phase 1 study in R/R NHL - - Initial data expected in the fourth quarter of 2021 - P...
-
Curis Announces Initiation of Investigator-Sponsored Phase 2 LUCAS Study of CA-4948 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate-Risk Myelodysplastic Syndromes - Phase 2 study sponsored by investigators at Universität Leipzig in Germany - ...
-
Curis to Present at B. Riley Securities Virtual Oncology Investor Conference PR Newswire LEXINGTON, Mass. , Jan. 14, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment o...